⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 16, 2024

Supplementary Figure S1 from (R)-2-hydroxyglutarate inhibits KDM5 histone lysine demethylases to drive transformation in IDH-mutant cancers

Kathryn Gunn Matti Myllykoski John Z. Cao Manna Ahmed Bofu Huang Betty Rouaisnel Bill H. Diplas Michael M. Levitt Ryan Looper John G. Doench Keith L. Ligon Harley I. Kornblum Samuel K. McBrayer Hai Yan Cihangir Duy Lucy A. Godley Peppi Koivunen Julie-Aurore Losman

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Characterization of isogenic TF-1 cell lines expressing TET2-targeting shRNAs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gunn et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db64358752337a https://doi.org/10.1158/2159-8290.27025190

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from (R)-2-hydroxyglutarate inhibits KDM5 histone lysine demethylases to drive transformation in IDH-mutant cancers2024
2Supplementary Figure S3 from (R)-2-hydroxyglutarate inhibits KDM5 histone lysine demethylases to drive transformation in IDH-mutant cancers2024
3Supplementary Figure S3 from (R)-2-hydroxyglutarate inhibits KDM5 histone lysine demethylases to drive transformation in IDH-mutant cancers2024
4Supplementary Figure S10 from (R)-2-hydroxyglutarate inhibits KDM5 histone lysine demethylases to drive transformation in IDH-mutant cancers2024
5Supplementary Figure S10 from (R)-2-hydroxyglutarate inhibits KDM5 histone lysine demethylases to drive transformation in IDH-mutant cancers2024